Vaccines <ul><li>Successes of the Past </li></ul><ul><li>Possibilities for the Future </li></ul>www.freelivedoctor.com
Vaccines <ul><li>Immunity to viral infections usually depends on the development of an immune response to </li></ul><ul><l...
Vaccines <ul><li>Minor role for internal proteins can be seen in influenza pandemics </li></ul><ul><li>New flu viral strai...
Vaccines <ul><li>Some viruses have more than one surface protein </li></ul><ul><li>Influenza (Orthomyxovirus) </li></ul><u...
Vaccines <ul><li>Neutralization may result from: </li></ul><ul><li>Binding of antibody to site on virus surface - block in...
Vaccines Addition points to note: Site in body at which virus replicates Three major sites for viral replication www.freel...
Three major sites for viral replication <ul><li>Mucosal surfaces of respiratory tract and GI tract.  Rhino; myxo; corona; ...
There is little point in having a good neutralizing humoral antibody in the circulation when the virus replicates, for exa...
Vaccines - Problems <ul><li>Different viruses may cause similar disease --e.g. common cold </li></ul><ul><li>Antigenic dri...
Vaccines - Problems <ul><li>Integration of viral DNA . Vaccines will not work on latent virions unless they express antige...
Smallpox www.freelivedoctor.com <ul><li>Mummies </li></ul><ul><li>China/India  Crusaders </li></ul><ul><li>W Europe: fatal...
Smallpox www.freelivedoctor.com <ul><li>Variolation </li></ul><ul><li>1% v. 25% mortality </li></ul><ul><li>Life-long immu...
Smallpox <ul><li>Vaccination </li></ul><ul><li>Jenner 1796 : Cowpox/Swinepox </li></ul><ul><li>1800’s Compulsory childhood...
Smallpox <ul><li>No animal reservoir </li></ul><ul><li>Lifelong immunity </li></ul><ul><li>Subclinical cases rare </li></u...
Polio Vaccine www.freelivedoctor.com <ul><li>Small RNA virus  Some drift…but not too far as non-viable </li></ul><ul><li>U...
Sabin Polio Vaccine <ul><li>Attenuation by passage in foreign host </li></ul><ul><li>More suited to foreign environment an...
Salk Polio Vaccine <ul><li>Formaldehyde-fixed </li></ul><ul><li>No reversion </li></ul>www.freelivedoctor.com
Polio Vaccine <ul><li>Why use the Sabin vaccine?: </li></ul><ul><li>Local immunity: Vaccine virus just like natural infect...
Polio Vaccine <ul><li>New CDC Guidelines </li></ul><ul><li>Last US natural (non-vaccine associated) case was 15 years ago ...
New Recommendations To eliminate the risk for Vaccine-Associated Paralytic Poliomyelitis, the ACIP recommended an all-inac...
Vaccines <ul><li>Activates all phases of immune system. Can get humoral IgG and local IgA </li></ul><ul><li>Raises immune ...
Vaccines <ul><li>Low cost </li></ul><ul><li>Quick immunity in majority of vaccinees </li></ul><ul><li>In case of polio and...
Vaccines <ul><li>Disadvantages of Live Attenuated Vaccine </li></ul><ul><li>Mutation; reversion to virulence (often freque...
Vaccines <ul><li>Advantages of inactivated vaccines </li></ul><ul><li>Gives sufficient humoral immunity if boosters given ...
New Methods <ul><li>Selection of attenuated virus strain </li></ul><ul><li>Varicella </li></ul><ul><li>Hepatitis A </li></...
New Methods Recent ‘flu vaccine from Aviron Passage progressively at cold temperatures TS mutant in internal proteins Can ...
New Methods <ul><li>Deletion mutants </li></ul><ul><li>Suppression unlikely (but caution in HIV) </li></ul><ul><li>Viable ...
New Methods www.freelivedoctor.com <ul><li>Recombinant DNA </li></ul><ul><li>Single gene (subunit) </li></ul>S-antigen mRN...
Single gene (subunit) - problems <ul><li>Surface glycoprotein poorly soluble - deletion? </li></ul><ul><li>Poorly immunoge...
Single gene (subunit) in expression vector <ul><li>Vaccinate with live virus </li></ul><ul><li>Canary Pox </li></ul><ul><l...
New Methods <ul><li>Chemically synthesized peptide </li></ul><ul><li>malaria </li></ul><ul><li>poorly immunogenic </li></u...
New methods Anti-idiotype vaccine epitope Antibody with epitope binding site Virus www.freelivedoctor.com antibody
Anti-idiotype vaccine  cont Make antibody against antibody idiotype Anti-idiotype antibody mimics the epitope www.freelive...
Anti-idiotype antibody  cont 2 Use anti-idiotype antibody as injectable vaccine Antibody to anti-idiotype  antibody Binds ...
New Methods <ul><li>New “Jennerian Vaccines” </li></ul><ul><li>Live vaccines derived from animal strains of similar viruse...
New Methods <ul><li>New Jennerian Vaccines </li></ul><ul><li>Bovine parainfluenza Type 3 </li></ul><ul><li>Bovine virus is...
New Methods www.freelivedoctor.com <ul><li>Second Generation Jennerian Vaccines </li></ul><ul><li>Rotavirus </li></ul><ul>...
Vaccines <ul><li>1796 Jenner:  wild type animal-adapted virus </li></ul><ul><li>1800’s Pasteur: Attenuated virus </li></ul...
DNA Vaccines plasmid Muscle cell Gene for antigen Muscle cell expresses protein - antibody made CTL response www.freelived...
DNA Vaccines <ul><li>Plasmids are  easily manufactured  in large amounts </li></ul><ul><li>DNA is  very stable </li></ul><...
DNA Vaccines <ul><li>Mixtures of plasmids  could be used that encode many protein fragments from a virus/viruses so that a...
DNA Vaccines <ul><li>Possible Problems </li></ul><ul><li>Potential integration of plasmid into host genome leading to  ins...
DNA Vaccines <ul><li>DNA vaccines produce a situation that reproduces a virally-infected cell </li></ul><ul><li>Gives: </l...
Towards an anti-HIV Vaccine <ul><li>Questions: </li></ul><ul><li>For a vaccine what are the measures of protection? </li><...
Towards an anti-HIV Vaccine www.freelivedoctor.com What should vaccine elicit? Humoral response neutralizing antibody kill...
Towards an anti-HIV Vaccine www.freelivedoctor.com Early faith in neutralizing antibodies backed by chimpanzee experiments...
Towards an anti-HIV Vaccine <ul><li>Chimp studies designed for success </li></ul><ul><li>Animals challenged with small dos...
Towards an anti-HIV Vaccine Since 1986: > 15 SUBUNIT VACCINES Based on gp160/gp120 All safe None effective Low levels of s...
Towards an anti-HIV Vaccine <ul><li>A Classical Approach? </li></ul><ul><li>December 1992: Live attenuated SIV vaccine pro...
Towards an anti-HIV Vaccine Humans: NEF deletion mutant www.freelivedoctor.com
Towards an anti-HIV Vaccine <ul><li>Live attenuated: </li></ul><ul><li>Pro:  </li></ul><ul><li>SIV with NEF deletion prote...
Towards an anti-HIV Vaccine <ul><li>Inactivated: </li></ul><ul><li>Pro:   Simple </li></ul><ul><li>Mimics natural infectio...
Towards an anti-HIV Vaccine <ul><li>Subunit vaccine: </li></ul><ul><li>Pro: </li></ul><ul><li>Safety </li></ul><ul><li>Con...
Towards an anti-HIV Vaccine <ul><li>Subunit in vector </li></ul><ul><li>Pro: </li></ul><ul><li>Potent cell-mediated immuni...
Towards an anti-HIV Vaccine <ul><li>Problems for all vaccines: </li></ul><ul><li>Enhancing antibody </li></ul><ul><li>Vacc...
Towards an anti-HIV Vaccine <ul><li>Summary of problems: </li></ul><ul><li>Virus can hide in cells </li></ul><ul><li>Cell-...
Upcoming SlideShare
Loading in...5
×

Vaccine

2,774

Published on

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
2,774
On Slideshare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
120
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Vaccine

  1. 1. Vaccines <ul><li>Successes of the Past </li></ul><ul><li>Possibilities for the Future </li></ul>www.freelivedoctor.com
  2. 2. Vaccines <ul><li>Immunity to viral infections usually depends on the development of an immune response to </li></ul><ul><li>Antigens on the virus surface </li></ul><ul><li>Antigens on the virus-infected cell </li></ul><ul><li>In most cases response to internal proteins has little effect on humoral immunity to infection </li></ul><ul><li>Humoral antibodies can be important diagnostically (HIV) </li></ul>www.freelivedoctor.com
  3. 3. Vaccines <ul><li>Minor role for internal proteins can be seen in influenza pandemics </li></ul><ul><li>New flu viral strain contains a novel glycoprotein </li></ul><ul><li>Pandemic virus contains internal proteins to which the population has already been exposed </li></ul><ul><li>Nevertheless the CTL response to internal proteins is important </li></ul>Surface glycoprotein = protective immunogen which must be identified for a logical vaccine www.freelivedoctor.com
  4. 4. Vaccines <ul><li>Some viruses have more than one surface protein </li></ul><ul><li>Influenza (Orthomyxovirus) </li></ul><ul><li>Hemagglutinin - attaches virus to cell receptor </li></ul><ul><li>Neuraminidase - involved in release of virus from cell </li></ul><ul><li>Hemagglutinin is major target: stimulates neutralizing antibody </li></ul>www.freelivedoctor.com
  5. 5. Vaccines <ul><li>Neutralization may result from: </li></ul><ul><li>Binding of antibody to site on virus surface - block interaction with receptor </li></ul><ul><li>Aggregation of virus by polyvalent antibody </li></ul><ul><li>Complement-mediated lysis </li></ul>www.freelivedoctor.com
  6. 6. Vaccines Addition points to note: Site in body at which virus replicates Three major sites for viral replication www.freelivedoctor.com
  7. 7. Three major sites for viral replication <ul><li>Mucosal surfaces of respiratory tract and GI tract. Rhino; myxo; corona; parainfluenza; respiratory syncytial; rota </li></ul><ul><li>Infection at mucosal surfaces followed by spread systemically via blood and/or neurones to target organs: picorna; measles; mumps; HSV; varicella; hepatitis A and B </li></ul><ul><li>Direct infection of blood stream via needle or bites and then spread to target organs: hepatitis B; alpha; flavi; bunya; rhabdo </li></ul><ul><li>Local immunity via IgA very important in 1 and 2. </li></ul>www.freelivedoctor.com
  8. 8. There is little point in having a good neutralizing humoral antibody in the circulation when the virus replicates, for example, in the upper respiratory tract. Clearly, here secreted antibodies are important. Although in the case of influenza serum antibodies may be important www.freelivedoctor.com
  9. 9. Vaccines - Problems <ul><li>Different viruses may cause similar disease --e.g. common cold </li></ul><ul><li>Antigenic drift and shift -- especially true of RNA viruses and those with segmented genomes </li></ul><ul><li>Shift: reassortment of segmented genomes (‘flu A but not rota or ‘flu B) </li></ul><ul><li>Drift: rapid mutation - retroviruses </li></ul><ul><li>Large animal reservoirs - Reinfection may occur </li></ul>www.freelivedoctor.com
  10. 10. Vaccines - Problems <ul><li>Integration of viral DNA . Vaccines will not work on latent virions unless they express antigens on cell surface. In addition, if vaccine virus integrates it may cause problems </li></ul><ul><li>Transmission from cell to cell via syncytia </li></ul><ul><li>Recombination of the virulent strain or of the vaccine virus </li></ul>www.freelivedoctor.com
  11. 11. Smallpox www.freelivedoctor.com <ul><li>Mummies </li></ul><ul><li>China/India Crusaders </li></ul><ul><li>W Europe: fatality rate 25% </li></ul><ul><li>History changed: </li></ul><ul><li>Cortes </li></ul><ul><li>Louis XIV </li></ul>
  12. 12. Smallpox www.freelivedoctor.com <ul><li>Variolation </li></ul><ul><li>1% v. 25% mortality </li></ul><ul><li>Life-long immunity: No drift or shift (proof reading) </li></ul><ul><li>UK: 1700’s </li></ul><ul><li>China 1950 </li></ul><ul><li>Pakistan/Afghanistan/Ethiopia 1970 </li></ul>
  13. 13. Smallpox <ul><li>Vaccination </li></ul><ul><li>Jenner 1796 : Cowpox/Swinepox </li></ul><ul><li>1800’s Compulsory childhood vaccination </li></ul><ul><li>1930’s Last natural UK case </li></ul><ul><li>1940’s last natural US case </li></ul><ul><li>1958 WHO program </li></ul><ul><li>October 1977: Last case (Somalia) </li></ul>www.freelivedoctor.com
  14. 14. Smallpox <ul><li>No animal reservoir </li></ul><ul><li>Lifelong immunity </li></ul><ul><li>Subclinical cases rare </li></ul><ul><li>Infectivity does not precede overt symptoms </li></ul><ul><li>One Variola serotype </li></ul><ul><li>Effective vaccine </li></ul><ul><li>Major commitment by governments </li></ul>www.freelivedoctor.com
  15. 15. Polio Vaccine www.freelivedoctor.com <ul><li>Small RNA virus Some drift…but not too far as non-viable </li></ul><ul><li>US: Sabin attenuated vaccine ~ 10 cases vaccine-associated disease per year </li></ul><ul><li>50% vaccinees feces </li></ul><ul><li>50% contacts </li></ul><ul><li>Vaccine-associated cases: revertants </li></ul><ul><li>1 in 4,000,000 vaccine infections paralytic polio </li></ul><ul><li>1 in 100 of wt infections </li></ul><ul><li>Scandinavia: Salk dead vaccine </li></ul><ul><li>No gut immunity </li></ul><ul><li>Cannot wipe out wt virus </li></ul>
  16. 16. Sabin Polio Vaccine <ul><li>Attenuation by passage in foreign host </li></ul><ul><li>More suited to foreign environment and less suited to original host </li></ul><ul><li>Grows less well in original host </li></ul><ul><li>Polio: </li></ul><ul><li>Monkey kidney cells </li></ul><ul><li>Grows in epithelial cells </li></ul><ul><li>Does not grow in nerves </li></ul><ul><li>No paralysis </li></ul><ul><li>Local gut immunity (IgA) </li></ul><ul><li>Pasteur rabies vaccine also attenuated </li></ul>www.freelivedoctor.com
  17. 17. Salk Polio Vaccine <ul><li>Formaldehyde-fixed </li></ul><ul><li>No reversion </li></ul>www.freelivedoctor.com
  18. 18. Polio Vaccine <ul><li>Why use the Sabin vaccine?: </li></ul><ul><li>Local immunity: Vaccine virus just like natural infection </li></ul><ul><li>Stopping replication in G.I. Tract stops viral replication TOTALLY </li></ul><ul><li>Dead Salk vaccine virus has no effect on gut replication </li></ul><ul><li>No problem with selective inactivation </li></ul><ul><li>Greater cross reaction as vaccine virus also has antigenic drift </li></ul><ul><li>Life-long immunity </li></ul>www.freelivedoctor.com
  19. 19. Polio Vaccine <ul><li>New CDC Guidelines </li></ul><ul><li>Last US natural (non-vaccine associated) case was 15 years ago </li></ul><ul><li>2 does injectable (Salk) vaccine </li></ul><ul><li>2 doses oral </li></ul><ul><li>Vaccine cases 1 in 3 million does </li></ul><ul><li>New strategy will prevent about 5 of the 10 vaccine-associated cases (the five found in vaccinees) </li></ul><ul><li>Cost $20 million </li></ul><ul><li>Savings from eradication $230 million </li></ul>www.freelivedoctor.com
  20. 20. New Recommendations To eliminate the risk for Vaccine-Associated Paralytic Poliomyelitis, the ACIP recommended an all-inactivated poliovirus vaccine (IPV) schedule for routine childhood polio vaccination in the United States. As of January 1, 2000 , all children should receive four doses of IPV at ages 2 months, 4 months, 6-18 months, and 4-6 years. www.freelivedoctor.com
  21. 21. Vaccines <ul><li>Activates all phases of immune system. Can get humoral IgG and local IgA </li></ul><ul><li>Raises immune response to all protective antigens. Inactivation may alter antigenicity. </li></ul><ul><li>More durable immunity; more cross-reactive </li></ul>Advantages of Attenuated Vaccines I www.freelivedoctor.com
  22. 22. Vaccines <ul><li>Low cost </li></ul><ul><li>Quick immunity in majority of vaccinees </li></ul><ul><li>In case of polio and adeno vaccines, easy administration </li></ul><ul><li>Easy transport in field </li></ul><ul><li>Can lead to elimination of wild type virus from the community </li></ul>Advantages of Attenuated Vaccines II www.freelivedoctor.com
  23. 23. Vaccines <ul><li>Disadvantages of Live Attenuated Vaccine </li></ul><ul><li>Mutation; reversion to virulence (often frequent) </li></ul><ul><li>Spread to contacts of vaccinee who have not consented to be vaccinated (could also be an advantage in communities where vaccination is not 100%) </li></ul><ul><li>Spread vaccine not standardized--may be back-mutated </li></ul><ul><li>Poor &quot;take&quot; in tropics </li></ul><ul><li>Problem in immunodeficiency disease (may spread to these patients) </li></ul>www.freelivedoctor.com
  24. 24. Vaccines <ul><li>Advantages of inactivated vaccines </li></ul><ul><li>Gives sufficient humoral immunity if boosters given </li></ul><ul><li>No mutation or reversion </li></ul><ul><li>Can be used with immuno-deficient patients </li></ul><ul><li>Sometimes better in tropics </li></ul><ul><li>Disadvantages of inactivated vaccines </li></ul><ul><li>Many vaccinees do not raise immunity </li></ul><ul><li>Boosters needed </li></ul><ul><li>No local immunity (important) </li></ul><ul><li>Higher cost </li></ul><ul><li>Shortage of monkeys (polio) </li></ul><ul><li>Failure in inactivation and immunization with virulent virus </li></ul>www.freelivedoctor.com
  25. 25. New Methods <ul><li>Selection of attenuated virus strain </li></ul><ul><li>Varicella </li></ul><ul><li>Hepatitis A </li></ul><ul><li>Use monoclonal antibodies to select for virus with altered surface receptor </li></ul><ul><li>Rabies </li></ul><ul><li>Reo </li></ul><ul><li>Use mutagen and grow virus at 32 degrees . Selects for temperature-sensitive virus. Grows in upper respiratory tract but not lower </li></ul><ul><li>‘ flu (new vaccine) </li></ul><ul><li>respiratory syncytial virus </li></ul>www.freelivedoctor.com
  26. 26. New Methods Recent ‘flu vaccine from Aviron Passage progressively at cold temperatures TS mutant in internal proteins Can be re-assorted to so that coat is the strain that is this years flu strain www.freelivedoctor.com
  27. 27. New Methods <ul><li>Deletion mutants </li></ul><ul><li>Suppression unlikely (but caution in HIV) </li></ul><ul><li>Viable but growth restrictions </li></ul><ul><li>Problems </li></ul><ul><li>Oncogenicity in some cases (adeno, retro) </li></ul>www.freelivedoctor.com
  28. 28. New Methods www.freelivedoctor.com <ul><li>Recombinant DNA </li></ul><ul><li>Single gene (subunit) </li></ul>S-antigen mRNA cDNA Express plasmid S-antigen mRNA protein Hepatitis B vaccine raised in yeast
  29. 29. Single gene (subunit) - problems <ul><li>Surface glycoprotein poorly soluble - deletion? </li></ul><ul><li>Poorly immunogenic </li></ul><ul><li>Post-translational modifications </li></ul><ul><li>Poor CTL response </li></ul>www.freelivedoctor.com
  30. 30. Single gene (subunit) in expression vector <ul><li>Vaccinate with live virus </li></ul><ul><li>Canary Pox </li></ul><ul><li>Infects human cells but does not replicate </li></ul><ul><li>Better presentation </li></ul><ul><li>CTL response </li></ul><ul><li>Vaccinia </li></ul><ul><li>Attenuated Polio </li></ul><ul><li>Being developed for anti-HIV vaccine </li></ul>www.freelivedoctor.com
  31. 31. New Methods <ul><li>Chemically synthesized peptide </li></ul><ul><li>malaria </li></ul><ul><li>poorly immunogenic </li></ul>www.freelivedoctor.com
  32. 32. New methods Anti-idiotype vaccine epitope Antibody with epitope binding site Virus www.freelivedoctor.com antibody
  33. 33. Anti-idiotype vaccine cont Make antibody against antibody idiotype Anti-idiotype antibody mimics the epitope www.freelivedoctor.com antibody Anti- idiotype antibody
  34. 34. Anti-idiotype antibody cont 2 Use anti-idiotype antibody as injectable vaccine Antibody to anti-idiotype antibody Binds and neutralizes virus Use as vaccine www.freelivedoctor.com Anti-anti-idiotype antibody Anti-idiotype antibody Anti-anti-idiotype antibody Anti-anti-idiotype antibody
  35. 35. New Methods <ul><li>New “Jennerian Vaccines” </li></ul><ul><li>Live vaccines derived from animal strains of similar viruses </li></ul><ul><li>Naturally attenuated for humans </li></ul><ul><li>Rotavirus: Monkey Rota </li></ul><ul><li>80% effective in some human populations </li></ul><ul><li>Ineffective in others </li></ul><ul><li>Due to differences in circulating viral serotypes </li></ul>www.freelivedoctor.com
  36. 36. New Methods <ul><li>New Jennerian Vaccines </li></ul><ul><li>Bovine parainfluenza Type 3 </li></ul><ul><li>Bovine virus is: </li></ul><ul><li>Infectious to humans </li></ul><ul><li>Immunogenic (61% of children get good response) </li></ul><ul><li>Poorly transmissable </li></ul><ul><li>Phenotypicaly stable </li></ul>www.freelivedoctor.com
  37. 37. New Methods www.freelivedoctor.com <ul><li>Second Generation Jennerian Vaccines </li></ul><ul><li>Rotavirus </li></ul><ul><li>11 segments of double strand RNA </li></ul><ul><li>Two encode: </li></ul><ul><li>VP4 (hemagglutinin) </li></ul><ul><li>VP7 (glycoprotein) </li></ul><ul><li>Co-infect tissue culture cells reassortment </li></ul><ul><li>10 segments from monkey rotavirus </li></ul><ul><li>1 segment outer capsid protein of each of four major rotavirus strains </li></ul><ul><li>Efficacy >80% </li></ul>Elicit neutralizing antibodies
  38. 38. Vaccines <ul><li>1796 Jenner: wild type animal-adapted virus </li></ul><ul><li>1800’s Pasteur: Attenuated virus </li></ul><ul><li>1996 DNA vaccines </li></ul><ul><li>The third vaccine revolution </li></ul>www.freelivedoctor.com
  39. 39. DNA Vaccines plasmid Muscle cell Gene for antigen Muscle cell expresses protein - antibody made CTL response www.freelivedoctor.com
  40. 40. DNA Vaccines <ul><li>Plasmids are easily manufactured in large amounts </li></ul><ul><li>DNA is very stable </li></ul><ul><li>DNA resists temperature extremes so storage and transport are straight forward </li></ul><ul><li>DNA sequence can be changed easily in the laboratory. This means that we can respond to changes in the infectious agent </li></ul><ul><li>By using the plasmid in the vaccinee to code for antigen synthesis, the antigenic protein(s) that are produced are processed (post-translationally modified) in the same way as the proteins of the virus against which protection is to be produced. This makes a far better antigen than purifying that protein and using it as an immunogen. </li></ul>www.freelivedoctor.com
  41. 41. DNA Vaccines <ul><li>Mixtures of plasmids could be used that encode many protein fragments from a virus/viruses so that a broad spectrum vaccine could be produced </li></ul><ul><li>The plasmid does not replicate and encodes only the proteins of interest </li></ul><ul><li>No protein component so there will be no immune response against the vector itself </li></ul><ul><li>Because of the way the antigen is presented, there is a CTL response that may be directed against any antigen in the pathogen. A CTL response also offers protection against diseases caused by certain obligate intracellular pathogens (e.g. Mycobacterium tuberculosis) </li></ul>www.freelivedoctor.com
  42. 42. DNA Vaccines <ul><li>Possible Problems </li></ul><ul><li>Potential integration of plasmid into host genome leading to insertional mutagenesis </li></ul><ul><li>Induction of autoimmune responses (e.g. pathogenic anti-DNA antibodies) </li></ul><ul><li>Induction of immunologic tolerance (e.g. where the expression of the antigen in the host may lead to specific non-responsiveness to that antigen) </li></ul>www.freelivedoctor.com
  43. 43. DNA Vaccines <ul><li>DNA vaccines produce a situation that reproduces a virally-infected cell </li></ul><ul><li>Gives: </li></ul><ul><li>Broad based immune response </li></ul><ul><li>Long lasting CTL response </li></ul><ul><li>Advantage of new DNA vaccine for flu: </li></ul><ul><li>CTL response can be against internal protein </li></ul><ul><li>In mice a nucleoprotein DNA vaccine is effective against a range of viruses with different hemagglutinins </li></ul>www.freelivedoctor.com
  44. 44. Towards an anti-HIV Vaccine <ul><li>Questions: </li></ul><ul><li>For a vaccine what are the measures of protection? </li></ul><ul><li>Can we overcome polymorphism? </li></ul><ul><li>What are the key antigens? </li></ul><ul><li>Attenuated or killed or neither? </li></ul><ul><li>Mucosal immunity critical? </li></ul><ul><li>Prevent infection or prevent disease? </li></ul><ul><li>Animal models </li></ul><ul><li>How does HIV kill cells anyway? </li></ul>www.freelivedoctor.com
  45. 45. Towards an anti-HIV Vaccine www.freelivedoctor.com What should vaccine elicit? Humoral response neutralizing antibody kill free virus Cellular response kill infected cells problem of cell-cell infection
  46. 46. Towards an anti-HIV Vaccine www.freelivedoctor.com Early faith in neutralizing antibodies backed by chimpanzee experiments HIV high levels of neutralizing antibody Can resist subsequent challenge by virus injected I.V. !!!! But not via rectum or vagina But chimps do not get AIDS
  47. 47. Towards an anti-HIV Vaccine <ul><li>Chimp studies designed for success </li></ul><ul><li>Animals challenged with small doses of virus at moment that antibody levels high (virus --not infected cells!) </li></ul><ul><li>Challenge virus same strain as that used to induce antibody </li></ul><ul><li>No vaccine made from one virus strain has protected chimps from another virus strain </li></ul><ul><li>Protection in man may not result from neutralizing antibodies at all </li></ul><ul><li>Ability to raise neutralizing antibodies in monkeys does not correlate with protection </li></ul><ul><li>Cell-mediated immunity is the key </li></ul><ul><li>This is also key in humans </li></ul><ul><li>HIV-exposed but not infected people shows signs of a cell-mediated response </li></ul>www.freelivedoctor.com
  48. 48. Towards an anti-HIV Vaccine Since 1986: > 15 SUBUNIT VACCINES Based on gp160/gp120 All safe None effective Low levels of strain-specific antibodies that quickly disappear Only ephemeral effects of cell-mediated immunity All done with gp160/gp120 of syncytium-inducing virus None tested on large groups of high risk people www.freelivedoctor.com
  49. 49. Towards an anti-HIV Vaccine <ul><li>A Classical Approach? </li></ul><ul><li>December 1992: Live attenuated SIV vaccine protected all monkeys for 2 years against massive dose of virus </li></ul><ul><li>All controls died </li></ul><ul><li>cell mediated immunity was key </li></ul>www.freelivedoctor.com
  50. 50. Towards an anti-HIV Vaccine Humans: NEF deletion mutant www.freelivedoctor.com
  51. 51. Towards an anti-HIV Vaccine <ul><li>Live attenuated: </li></ul><ul><li>Pro: </li></ul><ul><li>SIV with NEF deletion protects after ONE immunization </li></ul><ul><li>Long lived cell-mediated and humoral immunity </li></ul><ul><li>Possible herd immunity </li></ul><ul><li>Con: </li></ul><ul><li>Safety in immunodeficient people </li></ul><ul><li>LTR </li></ul><ul><li>Reversion </li></ul><ul><li>Need multiple strains: polymorphism </li></ul>www.freelivedoctor.com
  52. 52. Towards an anti-HIV Vaccine <ul><li>Inactivated: </li></ul><ul><li>Pro: Simple </li></ul><ul><li>Mimics natural infection </li></ul><ul><li>Protects against systemic and rectal challenge </li></ul><ul><li>No reversion </li></ul><ul><li>Con: </li></ul><ul><li>Polymorphism </li></ul><ul><li>LTR </li></ul><ul><li>Inactivation failure </li></ul>www.freelivedoctor.com
  53. 53. Towards an anti-HIV Vaccine <ul><li>Subunit vaccine: </li></ul><ul><li>Pro: </li></ul><ul><li>Safety </li></ul><ul><li>Con: </li></ul><ul><li>Ephemeral humoral response </li></ul><ul><li>Little cell mediated response </li></ul>www.freelivedoctor.com
  54. 54. Towards an anti-HIV Vaccine <ul><li>Subunit in vector </li></ul><ul><li>Pro: </li></ul><ul><li>Potent cell-mediated immunity </li></ul>www.freelivedoctor.com
  55. 55. Towards an anti-HIV Vaccine <ul><li>Problems for all vaccines: </li></ul><ul><li>Enhancing antibody </li></ul><ul><li>Vaccine may be immunosuppressive (anti-MHC) </li></ul>www.freelivedoctor.com
  56. 56. Towards an anti-HIV Vaccine <ul><li>Summary of problems: </li></ul><ul><li>Virus can hide in cells </li></ul><ul><li>Cell-cell transmission </li></ul><ul><li>Ethical problems </li></ul><ul><li>Lack of animal models </li></ul><ul><li>Immuno-silent sugars </li></ul><ul><li>Polymorphism/hypervariability: DRIFT </li></ul><ul><li>Activation of same cells that virus infects </li></ul><ul><li>Useless if T4 cells are depleted </li></ul><ul><li>Blood brain barrier </li></ul><ul><li>Oncogenicity </li></ul>www.freelivedoctor.com
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×